Default company panoramic image
Logo

MSC BioTarget

MSC is developing a class of medicinal substances with potential transformative innovations in the treatment of cancer.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Blauvelt, NY, USA
  • Currency USD
  • Founded January 2009

Company Summary

MSC's proprietary science platform has produced several unique drug candidates. The first patented compound is A250 which was developed as an extract from its patented fermented wheat germ ingredient. Many cancer patients currently use the branded version of FWGE called AvéUltra as an adjunct to their conventional cancer therapies, to help counteract a weakened immune system and other toxic effects of their oncologic regimens.

Team

  • Default avatar
    David Wales
    Co-founder

    David focuses on developing the FWGE science and MSC’s strategic relationships. David has over 16 years of experience in the innovative natural remedies market. He co-founded American BioSciences, a sister company to MSC Biotarget in 1999. Prior to starting ABS, he was co-founder and Vice President of Lane Labs.

  • Default avatar
    Mate Hidvegi, Ph.D.
    Co-founder

    Dr. Hidvegi is a Hungarian bio-chemist and inventor of FWGE. Dr. Hidvegi directs the research and development for FWGE related products.

  • Default avatar
    Rick Jahnke
    Co-founder

    Rick focuses on finance and operations. He also has over 16 years of experience in the innovative natural remedies market. He co-founded American BioSciences with David Wales in 1999. He was formerly the Director of Medical Sales with Lane Labs and held marketing and sales management positions at Stryker Medical.